NCT03212365View on ClinicalTrials.gov

Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

June 2, 2019

Study Completion Date

October 1, 2019

Conditions
Venous ThromboembolismDeep Venous ThrombosisPulmonary EmbolusReconstructive Surgery
Interventions
DRUG

Fixed dose

Participants will receive 40 mg enoxaparin twice daily

DRUG

Variable dose

Participants will receive 0.5mg/kg enoxaparin twice daily

Trial Locations (2)

84132

University of Utah, Salt Lake City

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

Stanford University

OTHER

lead

University of Utah

OTHER

NCT03212365 - Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery | Biotech Hunter | Biotech Hunter